ASCO 2017, page-3

Hi,
I remember one of the board members told me two AGM ago about there being a seller that was crippling the share price.Well it would appear by his own admission its Barrett. So unless things change I would imagine the next set of trial results will not elevate the share price.Just be another quick trading opp.
Just a matter of waiting for a deal or the move to FDA approval not much else will matter I think.
At least either of those possible announcements won't be telegraphed

Aloha.